Abstract | BACKGROUND: MATERIAL/METHODS:
PPAR-gamma DNA of 33 histologically different tumor cells was isolated, purified, and all coding regions were separately amplified by PCR. The coding exons were then analyzed by single-stranded conformational polymorphism (SSCP) and bidirectional DNA sequencing. RESULTS: CONCLUSIONS: We conclude that somatic mutations in the PPAR gene are exceedingly rare events in malignant tumor cells. This makes PPAR-gamma more unlikely to act as a tumor suppressor gene, making it a stable and suitable target for TZD biological cancer therapy.
|
Authors | Maximilian G Posch, Chuanbing Zang, Wolf Mueller, Ulrike Lass, Andreas von Deimling, Elena Elstner |
Journal | Medical science monitor : international medical journal of experimental and clinical research
(Med Sci Monit)
Vol. 10
Issue 8
Pg. BR250-4
(Aug 2004)
ISSN: 1234-1010 [Print] United States |
PMID | 15277984
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Brain Neoplasms
(genetics, secondary)
- Breast Neoplasms
(genetics, pathology)
- DNA Primers
- Female
- Humans
- Neoplasms
(genetics)
- Polymorphism, Single-Stranded Conformational
- Tumor Cells, Cultured
|